Sun Pharma shares in focus after US FDA issues eight observations for Halol facility
Sun Pharma shares
will be in focus on Monday after the company announced that the U.S. Food and Drug Administration (FDA) issued a Form-483 with eight observations for its Halol facility. The observations followed a Good Manufacturing Practices (GMP) inspection conducted between June 2 and June 13, the company said in a regulatory filing on Saturday.
'This is further to our update on Halol dated 16 December 2022,' the company said, referring to the warning letter the U.S. FDA had issued to the facility. The warning letter came close on the heels of the regulator placing the Halol facility under an import alert.
by Taboola
by Taboola
Sponsored Links
Sponsored Links
Promoted Links
Promoted Links
You May Like
Kulkas yang belum Terjual dengan Harga Termurah (Lihat harga)
provokepulse.com/id
Cari Sekarang
Undo
The warning letter had summarised violations concerning current good manufacturing practice (cGMP) regulations.
The Halol plant, one of Sun Pharma's key manufacturing units, was last inspected in May 2022 and remains under an import alert.
Also Read:
These 11 Nifty microcap stocks can rally 55-210% in the next 12 months
Live Events
Sun Pharma
reported a 19% year-on-year decline in consolidated net profit for the March quarter at Rs 2,154 crore, compared with Rs 2,659 crore a year earlier. Revenue from operations rose 8% YoY to Rs 12,959 crore, up from Rs 11,983 crore in the corresponding period last year.
However, on a sequential basis, both profit and revenue declined. Profit after tax fell 26% from Rs 2,913 crore in Q3FY25, while revenue dropped 5% from Rs 13,675 crore.
For the full financial year, net profit stood at Rs 10,965 crore, up from Rs 9,610 crore in the previous year. Total revenue rose 8.5% to Rs 52,578 crore from Rs 48,497 crore.
Also Read:
10 midcap stocks with more than 20 buy Calls: Analysts see up to 25% upside
Sun Pharma share price performance and outlook
According to Trendlyne, the average target price for Sun Pharma is Rs 1,981, suggesting a potential upside of about 17% from current levels. Among 36 analysts tracking the stock, the majority have a 'Buy' rating.
Technically, the stock's Relative Strength Index (RSI) stands at 46.2, indicating neutral momentum. The MACD is at 15.0, is below its Centre Line; this is a bearish indicator.
Also Read:
Swiggy, Radico Khaitan among 7 stocks on which brokerages initiated coverage, see up to 34% upside
Sun Pharma shares closed 0.1% higher at Rs 1,688.7 on the BSE in the previous session, while the Sensex fell 0.7%. The stock is down 11% year-to-date and has dropped 7% over the past six months.
(
Disclaimer
: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of the Economic Times)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Indian Express
32 minutes ago
- Indian Express
ACB arrests AMC estate inspector in disproportionate assets case
The Gujarat Anti-Corruption Bureau (ACB) arrested an estate inspector of the Ahmedabad Municipal Corporation (AMC) for alleged possession of disproportionate assets (DA) to the tune of Rs 3.07 crore, according to a statement. The ACB statement issued on Thursday stated that the accused Jignesh Surendra Shah, a Class-2 Estate/TDO Inspector of East Zone of the AMC, was booked and arrested for the alleged possession of disproportionate assets (DA) to the tune of Rs 3.07 crore, which it alleged was 102.47% disproportionate to his known sources of income. According to the statement, the ACB conducted its preliminary inquiry based on an application it received regarding Shah's allegedly disproportionate assets. The ACB said that the period of investigation ranged between April 1, 2012 and March 31, 2022, during which the officer had allegedly used unlawful means to accumulate disproportionate assets. The investigation is being carried out by ACB Police Inspector VD Chaudhary. Further probe into the matter is underway.
Time of India
39 minutes ago
- Time of India
Strict action will be taken against projects lacking proper permissions, says HYDRAA chief
Hyderabad: At the Times Home Hunt Property Expo held recently, Hyderabad Disaster Management and Asset Protection Agency (HYDRAA) commissioner A V Ranganath cautioned that any new projects lacking proper permissions or built on encroached land will face strict action. 'Only layouts approved before HYDRAA's formation on July 19 last year will be exempt. All others must comply with current regulations,' said Ranganath, noting that unchecked construction contributed significantly to urban issues like flooding and traffic congestion. HYDRAA was set up not just as a watchdog, he said, but also as a proactive body aimed at promoting sustainable and responsible urban development. 'HYDRAA is not just about demolitions. We are focused on creating a healthier, more environmentally conscious real estate ecosystem,' Ranganath added. The authority is working closely with other agencies to rejuvenate lakes, address urban flooding, and improve drainage infrastructure. He also pointed out that traffic congestion alone costs the state nearly Rs 300 crore in infrastructure loss, underscoring the need for better planning. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Giao dịch vàng CFDs với mức chênh lệch giá thấp nhất IC Markets Đăng ký Undo 'We received criticism that HYDRAA slowed real estate activity, but there were geopolitical concerns, delays in RERA clearances, and approval bottlenecks at GHMC and HMDA—also played a role. If a project is legally approved, we won't interfere. Our aim is to ensure compliance and environmental responsibility,' he said.
Time of India
39 minutes ago
- Time of India
JDA to construct 71 sector roads
Jaipur: With city roads deteriorating due to potholes, craters, and uneven surfaces, the Jaipur Development Authority (JDA) has decided to construct 71 sector roads under its annual road maintenance programme. Though these roads were part of the Master Plan 2025, the JDA had been unable to execute them earlier due to various delays. Now, a portion of the road maintenance fund will be allocated for their construction. "We have four categories of sector roads – A, B, C, and D. Out of 226 proposed A and B category roads in the Master Plan, 71 will now be developed. The civic body has already granted administrative and financial approval of Rs 454 crore for the project," a senior JDA official said. During the previous Congress govt, sector roads were prioritised by category, with 'A' being the most critical. A JDA engineer added that these 71 roads were selected based on future traffic needs and planned settlements along both sides. "Several rounds of discussions were held between zone deputy commissioners and zonal engineers to finalise the list of sector roads. We also considered the availability of land and the number of encroachments to be removed before selection. Hopefully, construction will proceed smoothly," said a JDA engineer. Officials confirmed that out of the 71 sector roads, six will be developed near Niwaru Road and Govindpura, 13 near Muralipura, nine in Mansarovar and Bhankrota, two near Delhi and Agra Roads, and 16 in the Vartika area. "Tenders have already been floated for some of them," an official added.
